Drug Trial Radar · NCT01564537
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
722
Actual
Start
Aug 1, 2012
Primary completion
Oct 1, 2014
Study completion Feb 8, 2022
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions
- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
IxazomibDrug
Ixazomib capsules
LenalidomideDrug
Lenalidomide capsules
DexamethasoneDrug
Dexamethasone tablets
PlaceboDrug
Ixazomib placebo-matching capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)Time frame: From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months)
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of Arkansas Medical Sciences
Little Rock, Arkansas
Pacific Cancer Medical Center Inc
Anaheim, California
West Contra Costa Healthcare District
Berkeley, California
University of Florida
Gainesville, Florida
Cancer & Blood Disease Center
Lecanto, Florida
Northwest Georgia Oncology Center
Marietta, Georgia
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Columbia University Medical Center
New York, New York
Blood and Cancer Clinic
Fayetteville, North Carolina
Scranton Hematology Oncology
Scranton, Pennsylvania
MUSC Hollings Cancer Center
Charleston, South Carolina
Fred Hutchinson Cancer Research
Seattle, Washington
West Virginia University Hospitals and Clinic
Morgantown, West Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Saint John Regional Hospital
Saint John, New Brunswick, Canada
CHUM Notre-Dame Hospital
Montreal, Quebec, Canada
MUHC Glen Site Cedars Cancer Centre
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.